Holen Sie sich die Stockscreener-App
1.88
1.20%
-0.03
Schlusskurs vom Vortag:
$1.91
Offen:
$1.9
24-Stunden-Volumen:
46,917
Relative Volume:
0.96
Marktkapitalisierung:
$183.17M
Einnahmen:
$5.15M
Nettoeinkommen (Verlust:
$-65.35M
KGV:
-0.9447
EPS:
-1.99
Netto-Cashflow:
$-20.85M
1W Leistung:
-1.20%
1M Leistung:
+2.83%
6M Leistung:
-36.03%
1J Leistung:
-33.56%
1-Tages-Spanne:
$1.8187
$1.90
1-Wochen-Bereich:
$1.77
$1.98
52-Wochen-Spanne:
$1.70
$3.7735
Cellectis Adr Stock (CLLS) Company Profile
Vergleichen Sie CLLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CLLS | 1.8503 | 183.17M | 5.15M | -65.35M | -20.85M | -1.99 |
| VRTX | 450.01 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.02 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 594.70 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.85 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.66 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Cellectis Adr Stock (CLLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2022-05-18 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-01-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-11-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-11-08 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-10-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-04-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-03-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-08-19 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-03-06 | Herabstufung | Goldman | Neutral → Sell |
| 2019-10-30 | Fortgesetzt | Guggenheim | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Neutral |
| 2019-03-14 | Eingeleitet | William Blair | Outperform |
| 2018-12-19 | Eingeleitet | Goldman | Neutral |
| 2018-07-16 | Eingeleitet | Barclays | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2017-09-05 | Herabstufung | SunTrust | Buy → Hold |
| 2017-09-05 | Bestätigt | Wells Fargo | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2017-02-28 | Eingeleitet | Wells Fargo | Outperform |
| 2016-04-05 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-03-02 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
| 2015-07-20 | Eingeleitet | BofA/Merrill | Buy |
| 2015-04-20 | Eingeleitet | Jefferies | Buy |
| 2015-04-20 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Cellectis Adr Aktie (CLLS) Neueste Nachrichten
European Equities Traded in the US as American Depositary Fall Sharply in Tuesday Trading - MSN
Cellectis's SWOT analysis: gene-editing firm's stock faces pivotal year ahead - Investing.com
Cellectis stock touches 52-week low at $1.75 amid market challenges - Investing.com
Earnings call: Cellectis reports robust cash reserves, new R&D initiatives - Investing.com
Baird maintains $10 target on Cellectis amid strong AZN partnership - Investing.com
Cellectis earnings missed by $0.03, revenue topped estimates By Investing.com - Investing.com South Africa
Cellectis earnings missed by $0.03, revenue topped estimates - Investing.com
Cellectis stock touches 52-week low at $1.77 amid market shifts By Investing.com - Investing.com South Africa
500: Something went wrong - Investing.com
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remains Down for Week - MSN
European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher - MSN
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN
Monthly information on share capital and company voting rights - GlobeNewswire Inc.
Wall Street SWOT: Cellectis stock rides wave of innovation amid biotech challenges - Investing.com
Wall Street SWOT: Cellectis stock rides wave of innovation amid biotech challenges By Investing.com - Investing.com South Africa
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading - MSN
A year in review: Cellectis ADR (CLLS)’s performance in the last year - US Post News
Monthly information on share capital and company voting rights - GlobeNewswire Inc.
Market Insights: Cellectis ADR (CLLS)'s Notable Drop of -5.84, Closing at 2.02 – DWinneX - The Dwinnex
Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors - The Globe and Mail
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results - The Globe and Mail
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading - MSN
Cellectis shares target cut by Oppenheimer on revised model post-Q1 results - Investing.com India
Cellectis shares target cut by Oppenheimer on revised model post-Q1 results By Investing.com - Investing.com UK
European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower - MSN
Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca By Investing.com - Investing.com India
Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca - Investing.com India
European Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Fall Again in Tuesday Trading - MSN
CellectisADR (CLLS) Price Target Increased by 20.85% to 11.75 - MSN
AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions - AstraZeneca
There's a Lot of Upside For Emerging Gene-Editing Companies - The Globe and Mail
Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing - Nature.com
Cytovia Therapeutics To Go Public Via $600 Million SPAC Merger - Equities News
Cellectis Completes Sale of $47 million through its ATM program - The Globe and Mail
Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq - The Globe and Mail
Current Cathie Wood Portfolio 2021: Ark Invest Holdings - New Trader U
The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon - Yahoo Finance
30 Stocks Moving In Wednesday's Pre-Market SessionAdtran Holdings (NASDAQ:ADTN), Adient (NYSE:ADNT) - Benzinga
7 Gene Editing Companies Investors Should Watch - Nanalyze
25 Stocks Moving In Tuesday's Pre-Market SessionBioCryst Pharma (NASDAQ:BCRX) - Benzinga
25 Stocks Moving In Monday's Pre-Market SessionAltisource Portfolio (NASDAQ:ASPS) - Benzinga
Top 10 Luxury Car Brands In The World - Insider Monkey
Cellectis (CLLS) Stock Price, News & AnalysisNASDAQ - MarketBeat
Morning Market GainersCellectis (NASDAQ:CLLS) - Benzinga
Finanzdaten der Cellectis Adr-Aktie (CLLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):